

Surgical Science Q4 2024 - Growth should ramp in 2025e, margins might lag

Redeye updates its estimates following Surgical Science's Q4 2024 report. While we judge top-line growth was solid, margins were rather soft. Surgical Science recently announced the closing of its Intelligent Ultrasound acquisition and that 100% of da Vinci 5 system will feature simulation with a subscription-based model. Further, the company won a larger Educational Products tender. We update our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking, www.redeye.se/

Attachments

Surgical Science Q4 2024 - Growth should ramp in 2025e, margins might lag